Next Lab Archimed

What Next Lab Archimed does

Next Lab Archimed (legally Next Lab Italy Srl) is an Italian private diagnostic laboratory founded in 2005 and headquartered in Milan, operating as part of the Next Clinics Group, a multi-country healthcare diagnostic organization. The company specializes in cytological, biochemical, and molecular genetic analyses across four service verticals: genetic testing (prenatal NIPT, oncogenetics, preconception carrier screening, molecular genetics), pathological anatomy (liquid-based cytology and histology), microbiology and virology (STI panels, SARS-CoV-2 PCR, microbiological swabs), and clinical biochemistry (prenatal serum screening). It serves both healthcare providers (gynecologists, oncologists, genetic counselors) and individual patients through three operational sites in Cernusco sul Naviglio, Busto Arsizio, and Pavia, with home sample collection available across Milan, Varese, Como, and Monza-Brianza provinces.

The laboratory's technical stack is built on Next Generation Sequencing (NGS) for gene panel and exome analysis, RT-PCR for infectious disease detection, array-CGH for molecular karyotyping, and BD SurePath liquid-based cytology — a partnership-licensed platform through which the lab processes over 100,000 Pap tests annually. Proprietary branded offerings include Prenatal Next (CE-IVD marked NIPT with over 99% specificity for T21, T18, T13 and 13 microdeletions), Oncocheck Hereditary Cancer (84-gene NGS panel), Duoscreen (UK-NEQAS certified first/second trimester biochemical screening with 90% detection rate), Next Carrier preconception screening, and a 5,000+ gene Clinical Exome plus 22,000-gene Whole Exome diagnostic service. Quality management at the Pavia site is certified under ISO 9001:2015 and SIGUCert standards.

The business model is professional-services based, generating revenue through appointment-based laboratory diagnostic testing delivered to a hybrid B2B/B2C customer base. Pricing is quote-based and not publicly disclosed; access is by phone, email, online form, or appointment at operational sites, with results delivered through dedicated patient and specialist portals. Patient acquisition is supported by content marketing (multi-language website in Italian, English, Spanish) and organic social channels (Facebook, Instagram, LinkedIn, YouTube). The legal entity is an Italian Società a responsabilità limitata with €10,000 share capital (VAT 12024890969, REA 1776706), and no venture or external equity funding has been disclosed.

Name

Next Lab Archimed

Legal name

Next Lab Italy Srl

Website

https://nextlabsitaly.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

Next Lab Archimed (Next Lab Italy Srl) is an Italian private diagnostic laboratory founded in 2005, offering genetic, cytological, microbiological, and biochemical testing to patients and referring healthcare specialists across Lombardy through three operational sites and home sample collection.

Ownership category

akta.pro rank

Product category

Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

Keywords

• Molecular diagnostics
• Genetic testing
• Prenatal screening
• Cytology services
• Microbiology testing

Headquarters

HQ city

Busto Arsizio

HQ country

Italy

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Laboratory Diagnostic Services: Next Lab Italy generates revenue through providing laboratory diagnostic testing services across four main areas: genetic testing (prenatal, oncogenetics, preconception, molecular genetics), pathological anatomy (cytology, histology), microbiology and virology testing, and clinical biochemistry screening. Services are provided to patients and healthcare specialists through appointment-based testing at their operational sites.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels7 records

Core offering

Next Lab Archimed is a private diagnostic laboratory operating in Busto Arsizio, Italy, providing four core service areas: genetic testing (prenatal, oncogenetics, preconception, and constitutional genetics), pathological anatomy (cytology and histology), microbiology and virology (STI panels, COVID-19), and clinical biochemistry analyses. The lab serves both healthcare specialists (gynecologists, oncologists, geneticists, hospitals) through a dedicated specialist portal, and individual patients directly via a patient portal with home self-sampling options.

Product overview

Next Lab Italy is a diagnostic laboratory offering genetic testing, pathological anatomy, and microbiology/virology services. Its product portfolio includes prenatal genetic testing (Prenatal Next NIPT, Panorama Test, Harmony Test, Array-CGH), oncogenetics (BRCA1/BRCA2 testing, Oncocheck Hereditary Cancer with up to 84 genes), molecular genetics (Clinical Exome, Whole Exome, Next Carrier), anatomical pathology (cytology including Pap tests using BD SurePath technology, histology), microbiology/virology (STI panels with RT-PCR, SARS-CoV-2 molecular testing, microbiological swabs), and clinical biochemistry (Duoscreen prenatal screening). Tests utilize advanced technologies including NGS (Next Generation Sequencing), RT-PCR, and array-CGH. The company operates multiple sites in Italy (Milan, Cernusco sul Naviglio, Busto Arsizio, Pavia) and is part of the Next Clinics group.

Differentiator

Problem solved

Functional benefit

Brands

• Oncocheck Hereditary Cancer: Genetic test analyzing up to 84 genes associated with common hereditary cancers including breast, ovarian, colorectal, pancreatic, and others.
• Prenatal Next
• Next Carrier
• DuoScreen
• Next Clinics

Products and services

• Genetic Testing Services Genetic analyses including prenatal screening (non-invasive prenatal testing, chorionic villus sampling, amniocentesis), oncogenetics (hereditary cancer panels for breast, ovarian, colon cancer), preconception screening, constitutional cytogenetics, and molecular genetics. Targets gynecologists, oncologists, genetic counselors, and patients seeking hereditary disease and prenatal risk assessment.
• Pathological Anatomy Services Cytological and histological analyses including liquid-based cytology (BD SurePath), conventional Pap smears, HPV testing, histological examinations, and immunohistochemical analyses. Designed for gynecologists, pathologists, and oncology departments requiring tissue and cell sample analyses.
• Microbiology and Virology Testing Diagnostic testing for sexually transmitted infections (STIs) and viral pathogens including COVID-19 (molecular and serological tests), HPV, and other infectious disease agents. Serves both clinics ordering diagnostic panels and patients requesting direct testing.
• Clinical Biochemistry Analyses Routine and specialized biochemical analyses on biological samples to support clinical decision-making. Targets physician offices and patients requiring standard biochemistry panels and specialized metabolic assessments.
• Home Self-Sampling Test Kits Self-collection kits enabling patients to collect samples (e.g., vaginal swabs, buccal swabs) at home and ship them to the lab for analysis. Targets individual consumers preferring privacy and convenience for STI screening, HPV testing, and genetic testing.

Quantifiable outcome

• Over 99% specificity for T21, T18, T13 chromosomal abnormalities
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Six partnerships are on record, tiered core and minor.

• BD (Becton, Dickinson and Company)coreTechnology or IntegrationNext Lab Italy utilizes BD SurePath liquid-based cytology technology for processing Pap tests. This technology provides fewer unsatisfactory results, greater diagnostic accuracy, and greater diagnostic reliability through a unique cell enrichment process. The laboratory processes over 100,000 Pap tests annually using this technology.
• Eo Ipso SrlminorImplementation/ SI/ Consulting PartnerThird-party service provider engaged for website maintenance and organization of digital campaigns. May have partial access to personal data as a result of contracted services.
• SeeHearSpeakUpminorOthersExternal independent whistleblowing system provider managing the transparency channel for reporting irregular or illegal actions within the Next Clinics Group including Next Lab Italy.
• MicrogenomicscoreTechnology or IntegrationMicrogenomics laboratory performs the Oncocheck Hereditary Cancer test using NGS – Next Generation Sequencing technology to analyze up to 84 genes associated with common hereditary cancers. The analysis is conducted at the Pavia operational site which maintains ISO 9001:2015 and SIGUCert quality certifications.
• UK-NEQASminorOthersExternal quality assessment service providing certification for Trisomy 21 detection in the Duoscreen prenatal biochemical screening test, ensuring accuracy and reliability of test results.
• DuoScreenminorOthersDuoScreen is a proprietary prenatal biochemical screening brand/trademark used by Next Lab Italy for first and second trimester screening tests, combining serum protein measurements with ultrasound assessments.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Dante Labs: Italian-founded genomics company offering whole genome and exome sequencing direct to consumers and providers. Comparable in NGS-based product offering and Italian origin, with stronger D2C brand and pan-European shipping.
• Bioscience Institute: Italian genetics and molecular diagnostics laboratory providing NIPT, hereditary cancer testing, and pharmacogenomics. Comparable in Italian market focus and genetic testing portfolio.
• Genomix4Life: Italian molecular diagnostics laboratory providing NGS-based genetic testing for clinical and research applications. Comparable technology stack and customer base, though smaller scale and narrower test menu.
• Igenomix: Reproductive genetics laboratory offering NIPT, preconception carrier screening, and preimplantation genetic testing. Comparable in prenatal and preconception test offerings, with international reach and IVF clinic partnerships.

Direct peers

• Centogene: European rare disease genetics laboratory offering exome sequencing, NIPT, and hereditary cancer testing. Comparable in molecular diagnostics portfolio and CE-IVD regulatory positioning.
• Eurofins Genoma Group: Italian molecular genetics laboratory offering prenatal screening, hereditary cancer panels, and clinical exome sequencing. Closely comparable product portfolio and customer base (Italian gynecologists, oncologists, and patients) directly overlap with Next Lab Italy.
• Breda Genetics: Italian genetics laboratory specializing in NIPT, preconception carrier screening, and hereditary cancer testing with NGS-based workflows. Direct competitor to Next Lab Italy in the Italian prenatal and oncogenetics market.

Broad incumbents

• Cerba Healthcare: European diagnostics provider with significant Italian presence offering reference laboratory services across genetics, pathology, and infectious disease. Overlapping test menu with broader geographic footprint and enterprise reach.
• Unilabs: European clinical diagnostics operator with Italian operations providing genetic, cytology, and microbiology testing. Comparable service mix at significantly greater scale and multi-country footprint.
• Synlab Italia: Italian arm of pan-European clinical laboratory network offering routine and specialized diagnostics including cytology, microbiology, and genetic testing. Comparable in service breadth but vastly larger scale and broader geographic coverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@NextLabItaly
• Facebookfacebook.com/Next-Lab-Italy-100064173278443
• LinkedInlinkedin.com/company/nextlabitaly
• Instagraminstagram.com/nextlabitaly

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Next Lab Archimed